Literature DB >> 20014463

Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Wei-Feng Shen1, Wei Zhong, Feng Xu, Tong Kan, Li Geng, Feng Xie, Cheng-Jun Sui, Jia-Mei Yang.   

Abstract

AIM: To understand the clinicopathological characteristics and treatment selections and improve survival and provide valuable information for patients with intrahepatic cholangiocarcinoma (ICC).
METHODS: We retrospectively evaluated 5311 liver cancer patients who received resection between October 1999 and December 2003. Of these, 429 (8.1%) patients were diagnosed with ICC, and their clinicopathological, surgical, and survival characteristics were analyzed.
RESULTS: Upper abdominal discomfort or pain (65.0%), no symptoms (12.1%), and hypodynamia (8.2%) were the major causes for medical attention. Laboratory tests showed 198 (46.4%) patients were HBsAg positive, 90 (21.3%) had alpha-fetoprotein > 20 microg/L, 50 (11.9%) carcinoembryonic antigen > 10 microg/L, and 242 (57.5%) carbohydrate antigen 19-9 (CA19-9) > 37 U/mL. Survival data was available for 329 (76.7%) patients and their mean survival time was 12.4 mo. The overall survival of the patients with R0, R1 resection and punching exploration were 18.3, 6.6 and 5.6 mo, respectively. Additionally, CA19-9 > 37 U/mL was associated with lymph node metastases, but inversely associated with cirrhosis. Multivariate analysis indicated that radical resection, lymph node metastases, macroscopic tumor thrombi and size, and CA19-9 were associated with prognosis.
CONCLUSION: Surgical radical resection is still the most effective means to cure ICC. Certain laboratory tests (such as CA19-9) can effectively predict the survival of the patients with ICC.

Entities:  

Keywords:  Diagnosis; Intrahepatic cholangiocarcinoma; Pathology; Surgery; Survival

Mesh:

Substances:

Year:  2009        PMID: 20014463      PMCID: PMC2795186          DOI: 10.3748/wjg.15.5976

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Extended resection for intrahepatic cholangiocarcinoma in Japan.

Authors:  M Yamamoto; K Takasaki; T Yoshikawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

2.  Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome.

Authors:  Manousos M Konstadoulakis; Sasan Roayaie; Ilias P Gomatos; Daniel Labow; Maria-Isabell Fiel; Charles M Miller; Myron E Schwartz
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

3.  [Hepatic lymph node involvement in patients with synchronous multiple liver metastases of colorectal cancer].

Authors:  Keiichiro Ishibashi; Tomonori Ohsawa; Masaru Yokoyama; Naoki Ishizuka; Tatsuya Miyazaki; Hiroshi Nakada; Tsuyoshi Gonda; Hideyuki Ishida
Journal:  Gan To Kagaku Ryoho       Date:  2006-11

4.  Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.

Authors:  M J Gaspar; I Arribas; M C Coca; M Díez-Alonso
Journal:  Tumour Biol       Date:  2001 Sep-Oct

5.  Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.

Authors:  Henrik Petrowsky; Peer Wildbrett; Daniela B Husarik; Thomas F Hany; Simona Tam; Wolfram Jochum; Pierre-Alain Clavien
Journal:  J Hepatol       Date:  2006-04-19       Impact factor: 25.083

6.  Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Nils R Frühauf; Marco Dömland; Andreas Paul; Eva-Maria Kind; Massimo Malagó; Christoph E Broelsch
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

7.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

8.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

9.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

10.  Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma.

Authors:  Ricardo Robles; Joan Figueras; Victor S Turrión; Carlos Margarit; Angel Moya; Evaristo Varo; Javier Calleja; Andres Valdivieso; Juan Carlos G Valdecasas; Pedro López; Manuel Gómez; Emilio de Vicente; Carmelo Loinaz; Julio Santoyo; Manuel Fleitas; Angel Bernardos; Laura Lladó; Pablo Ramírez; F S Bueno; Eduardo Jaurrieta; Pascual Parrilla
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

View more
  29 in total

Review 1.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Authors:  Shigeru Marubashi; Kunihito Gotoh; Hidenori Takahashi; Hiroaki Ohigashi; Masahiko Yano; Osamu Ishikawa; Masato Sakon
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

3.  Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database.

Authors:  Clancy J Clark; Christina M Wood-Wentz; Kaye M Reid-Lombardo; Michael L Kendrick; Marianne Huebner; Florencia G Que
Journal:  HPB (Oxford)       Date:  2011-09       Impact factor: 3.647

4.  The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy?

Authors:  Sameer H Patel; David A Kooby; Charles A Staley; Juan M Sarmiento; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2011-07-26       Impact factor: 3.647

5.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

6.  A simple and effective prognostic staging system based on clinicopathologic features of intrahepatic cholangiocarcinoma.

Authors:  Huabang Zhou; Xiaolan Jiang; Qiaomei Li; Jingyi Hu; Zhengrong Zhong; Hao Wang; Hui Wang; Bing Yang; Heping Hu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 7.  Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Authors:  Shun-ichi Ariizumi; Masakazu Yamamoto
Journal:  Surg Today       Date:  2014-09-25       Impact factor: 2.549

Review 8.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

Review 9.  Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Zheng Wang; Yuan-Yuan Sheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 10.  Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.

Authors:  Yun-Feng Wang; Fei-Ling Feng; Xu-Hong Zhao; Zhen-Xiong Ye; He-Ping Zeng; Zhen Li; Xiao-Qing Jiang; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.